Physician profile
Behrad Majidi
NPI 1295765386
$4,298.10
in general payments reported to CMS, 2019-2025
35 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $597 · 2023: $886 · 2024: $1,205 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,700.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,187.16 | 2022-2025 | |
| Lilly USA, LLC | $620.77 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $440.38 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $281.39 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $276.62 | 2022-2025 | |
| Amgen INC. | $218.43 | 2023-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $121.08 | 2023-2025 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $92.34 | 2024-2025 | Eliquis |
| Abbott Laboratories | $91.05 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.10 | 2023-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $71.06 | 2022 | |
| Axsome Therapeutics, INC. | $70.86 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals LP | $69.15 | 2024-2025 | Farxiga, Airsupra |
| Corcept Therapeutics | $65.25 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $56.69 | 2022-2023 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behrad Majidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.